Market Research Logo

Prostate Cancer - Pipeline Review, H1 2018

Prostate Cancer - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H1 2018, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 15, 118, 103, 7, 243, 34 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 10, 20, 58 and 21 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Prostate Cancer - Overview
Prostate Cancer - Therapeutics Development
Prostate Cancer - Therapeutics Assessment
Prostate Cancer - Companies Involved in Therapeutics Development
Prostate Cancer - Drug Profiles
Prostate Cancer - Discontinued Products
Prostate Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Prostate Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Prostate Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
Prostate Cancer - Pipeline by 4SC AG, H1 2018
Prostate Cancer - Pipeline by AB Science SA, H1 2018
Prostate Cancer - Pipeline by AbbVie Inc, H1 2018
Prostate Cancer - Pipeline by Abpro, H1 2018
Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2018
Prostate Cancer - Pipeline by ADC Therapeutics SA, H1 2018
Prostate Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2018
Prostate Cancer - Pipeline by Advantagene Inc, H1 2018
Prostate Cancer - Pipeline by Advaxis Inc, H1 2018
Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
Prostate Cancer - Pipeline by Aeolus Pharmaceuticals Inc, H1 2018
Prostate Cancer - Pipeline by Akshaya Bio Inc, H1 2018
Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc, H1 2018
Prostate Cancer - Pipeline by Alissa Pharma, H1 2018
Prostate Cancer - Pipeline by ALRISE Biosystems GmbH, H1 2018
Prostate Cancer - Pipeline by Altor BioScience Corp, H1 2018
Prostate Cancer - Pipeline by Ambrx Inc, H1 2018
Prostate Cancer - Pipeline by Amgen Inc, H1 2018
Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H1 2018
Prostate Cancer - Pipeline by AndroScience Corp, H1 2018
Prostate Cancer - Pipeline by AnGes Inc, H1 2018
Prostate Cancer - Pipeline by AntiCancer Inc, H1 2018
Prostate Cancer - Pipeline by Antigen Express Inc, H1 2018
Prostate Cancer - Pipeline by Antikor Biopharma Ltd, H1 2018
Prostate Cancer - Pipeline by Apcure SAS, H1 2018
Prostate Cancer - Pipeline by Aphios Corp, H1 2018
Prostate Cancer - Pipeline by APIM Therapeutics AS, H1 2018
Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H1 2018
Prostate Cancer - Pipeline by Aptose Biosciences Inc, H1 2018
Prostate Cancer - Pipeline by ARMO Biosciences Inc, H1 2018
Prostate Cancer - Pipeline by Armour Therapeutics Inc, H1 2018
Prostate Cancer - Pipeline by ArQule Inc, H1 2018
Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2018
Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2018
Prostate Cancer - Pipeline by Arvinas Inc, H1 2018
Prostate Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2018
Prostate Cancer - Pipeline by AstraZeneca Plc, H1 2018
Prostate Cancer - Pipeline by Athenex Inc, H1 2018
Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
Prostate Cancer - Pipeline by Autolus Ltd, H1 2018
Prostate Cancer - Pipeline by Avivia BV, H1 2018
Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2018
Prostate Cancer - Pipeline by Bayer AG, H1 2018
Prostate Cancer - Pipeline by BeiGene Ltd, H1 2018
Prostate Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2018
Prostate Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
Prostate Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
Prostate Cancer - Pipeline by BioAtla LLC, H1 2018
Prostate Cancer - Pipeline by BioNTech AG, H1 2018
Prostate Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2018
Prostate Cancer - Pipeline by Blirt SA, H1 2018
Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Prostate Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018
Prostate Cancer - Pipeline by Bukwang Pharm Co Ltd, H1 2018
Prostate Cancer - Pipeline by Camurus AB, H1 2018
Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Prostate Cancer - Pipeline by CanBas Co Ltd, H1 2018
List of Figures
Number of Products under Development for Prostate Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report